Goldman Sachs analyst Corinne Johnson started Fulcrum Therapeutics (FULC) with an Early-Stage Biotech rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $6 from $2 at BofA
- Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus
- Fulcrum Therapeutics Elects New Directors at Annual Meeting
- Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz